GLP1R and type 2 diabetes mellitus: Oral semaglutide is the first GLP1-RA developed for oral administration and it was approved for the treatment of T2D in adults by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) in 2020 [16].